ranitidine bismuth citrate profile

ranitidine bismuth citrate: Pylorid & Tritec are tradenames [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3033887
MeSH ID	M0198352

Synonym
gr-122311-x
ranitidine bismutrex
tritec
pylorid
ranitidine bismuth citrate (usan)
D05699
tritec (tn)
128345-62-0
elicodil
azamplus
helirad
n-(2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine, compound with bismuth(3(+)) citrate (1:1)
pylorisan
ranitidine bismuth citrate
unii-7aj51i17kg
Q3930120
ranitidine (bismuth citrate)
CS-0014408
HY-B0693A
ranitidine bismuth citrate (mart.)

Excerpt	Reference	Relevance
" Adverse reactions to these agents are mild, transient and infrequent, and reports of serious adverse reactions are rare."	( Review article: safety of bismuth in the treatment of gastrointestinal diseases. Dixon, JS; Drake, FM; Tillman, LA; Wood, JR, 1996)	0.29
" No adverse events were specifically attributed to ranitidine bismuth citrate."	( The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Bardhan, KD; Buckley, MJ; De Koster, EH; Duggan, AE; Gilvarry, J; Gummett, PA; Logan, RP; O'Morain, CA; Pounder, RE; Rauws, EA; Schaufelberger, HD; Wyeth, JW, 1996)	0.29
" Twenty-four patients experienced side-effects, but in only seven cases was treatment discontinued due to adverse events."	( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998)	0.3
" Three novel RBC-based triple therapies proved to be safe and well tolerated, with discontinuations due to side-effects occurring in less than 5% of cases."	( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998)	0.3

Excerpt	Reference	Relevance
" After the last dose the geometric mean for Cmax for 500 mg bid of GR122311X was 5 ng."	( Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). Frazer, NM; Keene, ON; Lacey, LF; Smith, JT, 1994)	0.29

Excerpt	Reference	Relevance
"To test eradication and adverse events of ranitidine bismuth citrate (RBC) when given with metronidazole and either oxytetracycline or spiramycin."	( Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Bang, CJ; Berstad, A; Coll, P; Hatlebakk, JG; Hausken, T; Nysaeter, G; Olafsson, S; Olafsson, T; Tefera, S, 1999)	0.3

Excerpt	Reference	Relevance
" This, in part, reflects the low systemic bioavailability of bismuth from these medicines: less than 1% of the bismuth dose administered is absorbed."	( Review article: safety of bismuth in the treatment of gastrointestinal diseases. Dixon, JS; Drake, FM; Tillman, LA; Wood, JR, 1996)	0.29

Excerpt	Relevance	Reference
" Thirty minutes after dosing each subject was given 375 ml of 99mTc-DTPA (diethylene triaminepentaacetic acid) labelled Clinifeed-ISO."	( Ranitidine bismuth citrate and ranitidine do not affect gastric emptying of a radio-labelled liquid meal. Bedding, AW; Farr, SJ; Forster, ER; Parikh, R; Smith, JT; Sweetland, J, 1994)	0.29
" Twenty four men with duodenal ulcers were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily or ranitidine 300 mg twice daily (double blind, randomised, parallel groups)."	( Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens. Fraser, AG; Hudson, M; Lam, WM; Luk, YW; Pounder, RE; Samloff, IM; Sawyerr, AM; Sercombe, J, 1993)	0.29
"To determine whether bismuth penetrates the gastric mucosa after dosing with ranitidine bismuth citrate."	( Gastric persorption of bismuth from ranitidine bismuth citrate. Fraser, AG; Lewin, JF; Pounder, RE, 1995)	0.29
"Bismuth particles were found to be interposed between epithelial cells in the antral mucosa of three of eight patients who were dosed with ranitidine bismuth citrate."	( Gastric persorption of bismuth from ranitidine bismuth citrate. Fraser, AG; Lewin, JF; Pounder, RE, 1995)	0.29
"Penetration of bismuth particles into the gastric mucosa may occur after oral dosing with ranitidine bismuth citrate."	( Gastric persorption of bismuth from ranitidine bismuth citrate. Fraser, AG; Lewin, JF; Pounder, RE, 1995)	0.29
"Disposition pharmacokinetics of bismuth following oral dosing of ranitidine bismuth citrate are complicated and variable."	( Modeling of trough plasma bismuth concentrations. Bennett, JE; Lacey, LF; Wakefield, JC, 1997)	0.3
" Such a synergistic effect probably explains the increased efficacy of RBC-clarithromycin dual therapies compared with clarithromycin dosed with acid-suppressive agents such as H2-receptor antagonists or proton-pump inhibitors."	( New options in Helicobacter pylori eradication: efficacy, resistance and synergy. Pipkin, GA; Williamson, R; Wood, JR, 1998)	0.3
" After dosing with bismuth alone or in association with ranitidine hydrochloride, bismuth was detected in several organs and deposition was not influenced by gastric pH."	( Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate. Canena, J; Leitão, J; Pinheiro, T; Pinto, AS; Quina, MG; Reis, J; Santos, AM, 1998)	0.3
" dosing schedule: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT): RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA); RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)."	( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998)	0.3
"In order to improve the efficacy and simplicity of the FDA-approved regimen of ranitidine bismuth citrate (RBC) and clarithromycin dual therapy, we added an inexpensive antibiotic (metronidazole), changed the dosage scheme to twice daily dosing, and decreased the duration of therapy to 1 week."	( Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. Cave, DR; Hoffman, JS; Katz, LM, 1999)	0.3
" Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens."	( Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999)	0.3
" pylori treatment: effectiveness (>80%), simplicity (twice-daily dosing and excellent compliance) and safety (low incidence of adverse effects)."	( First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P, 2007)	0.34

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	77 (46.67)	18.2507
2000's	82 (49.70)	29.6817
2010's	4 (2.42)	24.3611
2020's	2 (1.21)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	101 (59.06%)	5.53%
Reviews	27 (15.79%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	43 (25.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (51)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized,2-way Crossover, Bioequivalence Study of Ranitidine 300 mg Tablets Zantac 300 mg Tablets Administered as 1 x 300 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01131702]	Phase 1	24 participants (Actual)	Interventional	2003-01-31	Completed
Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration [NCT04397445]	Phase 1	18 participants (Actual)	Interventional	2020-06-08	Completed
The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR) [NCT02123498]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to IRB not approved)
The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Male and Female Subjects of 50-65 Years (Randomized, Open [NCT02172417]	Phase 1	18 participants (Actual)	Interventional	2000-07-31	Completed
A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain: A Double-Blind, Randomized, Controlled Trial [NCT02197143]	Phase 4	286 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Subjects [NCT03468777]	Phase 1	18 participants (Actual)	Interventional	2018-03-06	Terminated(stopped due to The study has been terminated due to pending data analysis)
A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formula [NCT02195804]	Phase 1	42 participants (Actual)	Interventional	2009-05-31	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial. [NCT02170792]	Phase 1	30 participants (Actual)	Interventional	2001-02-28	Completed
Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects [NCT01209455]		24 participants (Anticipated)	Interventional	2011-01-31	Recruiting
An 8 Week Non-selected Cohort Study to Investigate Whether the Treatment of Reflux Induced Cough Alters Associated Bronchial Hyper-responsiveness [NCT00668317]	Phase 3	5 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Primary care physicians began prescribing antacid therapy for chronic cough)
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued [NCT00633672]	Phase 3	400 participants (Anticipated)	Interventional	2001-02-28	Completed
Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block [NCT02441673]	Phase 2	130 participants (Anticipated)	Interventional	2018-10-12	Not yet recruiting
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Dai [NCT00401752]	Phase 3	397 participants (Actual)	Interventional	2006-03-31	Completed
Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting (AIRDOC) [NCT00585351]		100 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor [NCT05298683]	Phase 2	108 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00839306]	Phase 3	240 participants (Actual)	Interventional	2008-08-31	Completed
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00838526]	Phase 3	240 participants (Actual)	Interventional	2008-08-31	Completed
An Open-Label, 3-Period, Fixed Sequence Study to Evaluate the Effect of an H2 Antagonist and a Proton Pump Inhibitor on the Single Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects [NCT05338502]	Phase 1	20 participants (Actual)	Interventional	2019-07-08	Completed
[NCT02733640]		42 participants (Actual)	Interventional	2012-10-31	Completed
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects [NCT00930670]	Phase 4	320 participants (Actual)	Interventional	2009-06-30	Completed
In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial [NCT02700087]		0 participants (Actual)	Interventional	2016-02-29	Withdrawn
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis [NCT02555852]		4,238,504 participants (Actual)	Observational	2011-09-30	Completed
Cross-over Trial of Medical Treatment for GERD in Preterm Infants [NCT00131248]	Phase 3	18 participants (Actual)	Interventional	2004-04-30	Completed
A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects [NCT01908257]	Phase 1	16 participants (Actual)	Interventional	2013-07-31	Completed
Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents [NCT01976078]		45 participants (Actual)	Observational	2012-09-30	Completed
Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial [NCT02004197]	Phase 2/Phase 3	176 participants (Actual)	Interventional	2010-01-31	Completed
Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study. [NCT00590928]	Phase 4	75 participants (Actual)	Interventional	2004-07-31	Completed
An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the [NCT01682408]	Phase 1	28 participants (Actual)	Interventional	2012-09-30	Completed
A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain [NCT01332630]	Phase 2	24 participants (Actual)	Interventional	2011-08-16	Completed
[NCT00633412]	Phase 3	400 participants (Anticipated)	Interventional	2001-02-28	Completed
A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study [NCT00702871]	Phase 4	50 participants (Actual)	Interventional	2005-03-31	Completed
A Study to Evaluate the Effects of Two Different Meal Types, Omeprazole and Ranitidine on Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Subjects [NCT01392755]	Phase 1	32 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions [NCT00405119]	Phase 2	92 participants (Actual)	Interventional	2006-05-31	Completed
Comparative Randomized Controlled Trial Study of General Balanced Anesthesia Based on Opioid and Opioid Sparing Balanced Anesthesia for Cholecystectomy Surgery Via Laparoscopy: Intraoperative and Postoperative Outcomes [NCT02953210]	Phase 4	40 participants (Anticipated)	Interventional	2016-11-30	Enrolling by invitation
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3 [NCT00002106]	Phase 2	104 participants	Interventional		Completed
Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin [NCT01287520]	Phase 1	41 participants (Actual)	Interventional	2007-11-30	Completed
Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subj [NCT03011463]	Phase 1	24 participants (Actual)	Interventional	2016-11-30	Completed
YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers [NCT01538797]	Phase 1	22 participants (Actual)	Interventional	1996-07-31	Completed
A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine [NCT01539655]	Phase 1	34 participants (Actual)	Interventional	2012-02-29	Completed
Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor [NCT00161200]	Phase 3	60 participants	Interventional	2002-12-31	Terminated(stopped due to slow accrual)
Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) [NCT02999633]	Phase 2	14 participants (Actual)	Interventional	2017-03-08	Terminated(stopped due to Due to an unsatisfactory benefit/risk ratio, as specified in & 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely)
A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer [NCT00247130]	Phase 4	0 participants (Actual)	Interventional	2005-10-31	Withdrawn(stopped due to Superiority of iv omeprazole to ranitidine has already been proven by others.)
Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study) [NCT00247715]		664 participants (Actual)	Interventional	2003-10-31	Completed
Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial. [NCT01737840]	Phase 4	66 participants (Actual)	Interventional	2012-10-31	Completed
The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet) [NCT00000964]	Phase 1	6 participants	Interventional		Completed
A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma [NCT00030992]	Phase 2	102 participants (Actual)	Interventional	2002-02-28	Completed
Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study [NCT03140033]	Phase 2	158 participants (Anticipated)	Interventional	2016-07-31	Recruiting
A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations [NCT00527878]	Phase 2	16 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Failure to enroll adequate patient numbers due to small number of eligible patients)
Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study [NCT01896557]	Phase 4	92 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized Controlled Study Comparing the Prophylactic Effect of histamine1 and Histamine 2 Receptor Blocker in Prevention Systolic Hypotension After Protamine Administration in Cardiac Patient Having Cardiopulmonary Bypass [NCT03583567]	Phase 4	40 participants (Actual)	Interventional	2018-09-05	Completed
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity [NCT03145012]	Phase 4	30 participants (Actual)	Interventional	2018-05-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00030992 (2) [back to overview]	Number of Participants With Adverse Events
NCT00030992 (2) [back to overview]	Response Rate
NCT00131248 (1) [back to overview]	Bradycardia Episodes/Day
NCT00401752 (6) [back to overview]	The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.
NCT00401752 (6) [back to overview]	Percentage of Participants With the Occurance of Any Adverse Event.
NCT00401752 (6) [back to overview]	The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00401752 (6) [back to overview]	The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy
NCT00401752 (6) [back to overview]	The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00401752 (6) [back to overview]	The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00527878 (4) [back to overview]	New Skin Infections
NCT00527878 (4) [back to overview]	Clinical Severity Score
NCT00527878 (4) [back to overview]	New Lung Infections
NCT00527878 (4) [back to overview]	Number of Infections in Subjects With HIES.
NCT00585351 (2) [back to overview]	Prevention of Chemical Pneumonitis
NCT00585351 (2) [back to overview]	The Benefit of Advanced Notification in Promoting Informed Consent
NCT00668317 (1) [back to overview]	Change in Methacholine Sensitivity
NCT00838526 (3) [back to overview]	Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00838526 (3) [back to overview]	Percentage of Participants With Adverse Events by Category
NCT00838526 (3) [back to overview]	Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT00839306 (2) [back to overview]	Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00839306 (2) [back to overview]	Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314
NCT01287520 (10) [back to overview]	PK Parameter: Cmax of Free Carboplatin
NCT01287520 (10) [back to overview]	PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01287520 (10) [back to overview]	PK Parameter: AUC0-∞ of Free Carboplatin (Carb)
NCT01287520 (10) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314
NCT01287520 (10) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]	Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])
NCT01287520 (10) [back to overview]	Number of Participants With Best Overall Tumor Response
NCT01332630 (1) [back to overview]	Overall Response Rate (ORR)
NCT01737840 (2) [back to overview]	Visual Analogue Scale Score
NCT01737840 (2) [back to overview]	Need for Additional Drug
NCT01896557 (4) [back to overview]	Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment
NCT01896557 (4) [back to overview]	Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.
NCT01896557 (4) [back to overview]	Comparison of the Primary Outcome With Bioimpedance Aggregometry
NCT01896557 (4) [back to overview]	Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)
NCT02999633 (1) [back to overview]	Percentage of Participants With Objective Response
NCT04397445 (6) [back to overview]	Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration
NCT04397445 (6) [back to overview]	Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)
NCT04397445 (6) [back to overview]	Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)
NCT04397445 (6) [back to overview]	Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration
NCT04397445 (6) [back to overview]	AUC(0-t) of Plasma DMA
NCT04397445 (6) [back to overview]	AUC(0-t) of Plasma Ranitidine

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00030992)
Timeframe: 10 years

Intervention	Participants (Number)
BMS-247550	99

[back to top]

Response Rate

Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00030992)
Timeframe: 6 weeks

Intervention	Percentage of participants (Number)
	Complete response	Partial Response	Progressive disease	Stable disease
BMS-247550	1	9.4	12.6	76.8

[back to top]

Bradycardia Episodes/Day

(NCT00131248)
Timeframe: 7 days

Intervention	episodes per day (Mean)
Medications	4.6
Placebo	3.6

[back to top]

The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.

"Healed was defined as the absence of gastric ulcers. It was calculated as the proportion of subjects whose gastric ulcer(s) healed after 4 weeks treatment.~(Ulcers were on S stage, stage 1 = Nonblanchable erythema of intact skin, stage 2 = Partial thickness skin loss involving epidermis, dermis, or both, stage 3 = Full thickness skin loss involving damage to or necrosis of subcutaneous tissue, stage 4 = Full thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures or absent)." (NCT00401752)
Timeframe: 4 weeks

Intervention	Percentage of participants (Number)
Esomeprazole	59.4
Ranitidine	59.5

[back to top]

Percentage of Participants With the Occurance of Any Adverse Event.

Safety evaluation including vital signs, physical examination, ECG, adverse events and clinical laboratory evaluations during 8 weeks treatment. (NCT00401752)
Timeframe: 8 weeks

Intervention	Percentage of participants (Number)
Esomeprazole	16.8
Ranitidine	22.7

[back to top]

The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Healed was defined as the absence of ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose duodenal ulcer healed after 4 and 8 weeks treatment. (NCT00401752)
Timeframe: 4 and 8 week

Intervention	Percentage of participants (Number)
Esomeprazole	93.3
Ranitidine	81.8

[back to top]

The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy

Healed was defined as the absence of ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose gastric and duodenal ulcer healed after 4 and 8 weeks treatment. (NCT00401752)
Timeframe: 4 & 8 weeks

Intervention	Percentage of participants (Number)
Esomeprazole	80.2
Ranitidine	69.4

[back to top]

The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Healed was defined as the absence of gastric ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose gastric ulcer(s) healed after 8 weeks treatment. (NCT00401752)
Timeframe: 8 weeks

Intervention	Percentage of participants (Number)
Esomeprazole	81.1
Ranitidine	73.9

[back to top]

The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Resolution rate of investigator-assessed GI symptoms, including heartburn, acid regurgitation, nausea, abdominal fullness and sleep disorder. It was calculated as the percentage of subjects whose heartburn symptoms were resolved at Week 8. (NCT00401752)
Timeframe: week 4 and week 8

Intervention	Percentage of participants (Number)
Esomeprazole	100
Ranitidine	97.7

[back to top]

New Skin Infections

Patients reported the number of new skin infections (NCT00527878)
Timeframe: 12 months placebo/12 months ranitidine

Intervention	skin infections (Median)
Placebo	1
Ranitidine	0

[back to top]

Clinical Severity Score

Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe. (NCT00527878)
Timeframe: one year on ranitidine and one year on placebo

Intervention	score on a scale (Mean)
Placebo	9.8
Ranitidine	8.5

[back to top]

New Lung Infections

Number of new infection while on placebo or study drug (NCT00527878)
Timeframe: 12 months placebo and 12 months ranitidine

Intervention	new lung infections (Median)
Placebo	1
Ranitidine	0

[back to top]

Number of Infections in Subjects With HIES.

Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage). (NCT00527878)
Timeframe: 1 year on intervention

Intervention	infections (Median)
Placebo	4
Ranitidine	4

[back to top]

Prevention of Chemical Pneumonitis

Number of subjects that did not develop aspiration pneumonia in the intervention group (Ranitidine vs. placebo). (NCT00585351)
Timeframe: Assessed on the day of discharge (average length of stay is approximately 3-7 days)

Intervention	Participants (Number)
Advanced Notification + Ranitidine	5
No Advanced Notification + Ranitidine	7
Advanced Notification + Placebo	6
No Advanced Notification + Placebo	3

[back to top]

The Benefit of Advanced Notification in Promoting Informed Consent

Number of subjects that provided informed consent for study (advanced notification vs. no advanced notification). (NCT00585351)
Timeframe: Assessed at time of enrollment into the study.

Intervention	Participants (Number)
Advanced Notification	27
No Advanced Notification	25

[back to top]

Change in Methacholine Sensitivity

"Concentration of methacholine (mg/ml) at which participants forced expired volume in 1 sec (FEV1) is reduced by 20% (the provocation concentration of methacholine causing a 20% fall in FEV1-PC20).~To measure if there is a significant difference in PC20 recorded at baseline to that recorded following 8 weeks treatment with omeprazole and ranitidine" (NCT00668317)
Timeframe: baseline and 8 weeks

Intervention	mg/ml (Mean)
Omeprazole and Ranitidine	0.598

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference. (NCT00838526)
Timeframe: Baseline to Week 26

Intervention	Percentage of Participants (Number)
RAN 150mg BID	32.9
RAB ER 50mg QD	84.9

[back to top]

Percentage of Participants With Adverse Events by Category

An adverse event (AE) was any untoward medical occurrence in a participant administered an investigational product. A treatment emergent AE (TEAE) was any AE beginning on or after the confirmed date of first dose of study medication, up to and including 7 days after the last dose of study medication. A TEAE was considered related to study treatment if a causal relationship between the study treatment and the AE was a reasonable possibility. AEs were graded as severe if they were incapacitating, with inability to work or to perform normal daily activity. Serious AEs (SAEs) were events that resulted in death, were life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or were a congenital anomaly/birth defect. (NCT00838526)
Timeframe: From the time of administration of the first dose of study drug up to a maximum of approximately 30 weeks.

Intervention	Percentage of participants (Number)
	Any TEAE	Treatment-related TEAE	Severe TEAE	Severe, treatment-related TEAE	Death	Other SAE	Treatment-related SAE	TEAEs leading to discontinuation of treatment
RAB ER 50mg QD	64.2	14.5	8.1	0.6	0	6.4	0	6.9
RAN 150mg BID	47.5	8.5	3.4	1.7	0	1.7	0	6.8

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities). (NCT00838526)
Timeframe: Baseline to Week 26

Intervention	Percentage of Participants (Number)
	Yes	No	Missing
RAB ER 50mg QD	57.4	18.8	23.9
RAN 150mg BID	8.5	25.4	66.1

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

"eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00839306)
Timeframe: Baseline to Week 26

Intervention	Percentage of Participants (Number)
RAN 150mg BID	31.7
RAB ER 50mg QD	88.4

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Intervention	Percentage of Participants (Number)
	Yes	No	Missing
RAB ER 50mg QD	53.7	17.5	28.8
RAN 150mg BID	8.3	16.7	75

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314

(NCT01287520)
Timeframe: Cycle 1 Day 1 of a 28-day cycle

Intervention	nanograms per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)	122
LY 20/Carb 6/Pem 500 (Cohort 3)	246
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9 )	603
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7	898
LY 120/Carb 6/Pem 500 (Cohort 6)	1700
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)	881

[back to top]

PK Parameter: Cmax of Free Carboplatin

Cmax of free Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1, Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Intervention	nanograms/milliliter/milligram (Geometric Mean)
Carboplatin (Doublet Therapy)	24.0
Carboplatin (Triplet Therapy)	25.5

[back to top]

PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

AUC0-∞ was calculated from the area under the concentration versus time curves of LY2090314 from time zero to infinity when coadministered with Pem and Carb. (NCT01287520)
Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Intervention	nanograms*hour per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)	192
LY 20/Carb 6/Pem 500 (Cohort 3)	404
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)	938
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)	1830
LY 120/Carb 6/Pem 500 (Cohort 6)	2190
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)	1570

[back to top]

PK Parameter: AUC0-∞ of Free Carboplatin (Carb)

AUC0-∞ of free Carb was calculated from the area under the concentration versus time curves of Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Intervention	hours*nanograms per milliliter per mg (Geometric Mean)
Carboplatin (Doublet Therapy)	81.6
Carboplatin (Triplet Therapy)	88.1

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314

AUC0-∞ was calculated from the area under the concentration versus time curve from time 0 to infinity of LY2090314 when administered alone. (NCT01287520)
Timeframe: Cycle 1 Day 1 of a 28 day cycle

Intervention	nanograms*hour per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)	216
LY 20/Carb 6/Pem 500 (Cohort 3)	427
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)	976
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)	1870
LY 120/Carb 6/Pem 500 (Cohort 6)	3310
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)	1600

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)

AUC0-∞ was calculated from the area under the concentration versus time curves of Pem given as a single dose with Carb (doublet therapy) and when co-administered with Carb and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Intervention	hours*nanograms/milliliter/ milligram (Geometric Mean)
Pemetrexed (Doublet Therapy)	212
Pemetrexed (Triplet Therapy)	202

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

(NCT01287520)
Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Intervention	nanograms per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)	106
LY 20/Carb 6/Pem 500 (Cohort 3)	271
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)	657
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)	1150
LY 120/Carb 6/Pem 500 (Cohort 6)	768
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)	1040

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)

Cmax of Pem given as a single dose with Carb (doublet therapy) and when coadministered with Carb and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Intervention	nanogram per milliliter per milligram (Geometric Mean)
Pemetrexed (Doublet Therapy)	109
Pemetrexed (Triplet Therapy)	108

[back to top]

Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])

Recommended Phase 2 MTD was determined, when a dose limiting toxicity (DLT) occurred in 1 of 3 participants, the cohort was to be expanded to 6 participants. If a DLT occurred in 2 or more participants, accrual to the cohort was stopped, as the MTD was exceeded. A DLT was defined as an adverse event (AE) occurring in Cycle 1 (28 days) that was possibly related to study drug and met 1 of the following criteria: According to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0, ≥Grade 3 nonhematologic toxicity (except for nausea/vomiting without maximal symptomatic/prophylactic treatment) possibly or likely related to the study medication;CTCAE Grade 4 hematological toxicity of >5 days duration; Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; CTCAE ≥Grade 2 thrombocytopenia plus bleeding; CTCAE ≥Grade 3 prolonged QTc interval. (NCT01287520)
Timeframe: Baseline up to Day 28 (Cycle 1)

Intervention	milligrams (mg) (Number)
LY2090314/Pemetrexed/Carboplatin	40

[back to top]

Number of Participants With Best Overall Tumor Response

Best overall observed tumor response at any point during the study until disease progression/recurrence defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as at least 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria. (NCT01287520)
Timeframe: Baseline up to Cycle 9 (Cycle 1 was 28 days, Cycles 2 to 9 were 21 days)

,,,,,,,,

Intervention	participants (Number)
	CR	PR	SD	PD	Unknown (discontinued before response assessment)
LY 10/Carb 5/Pem 500 (Cohort 1)	0	0	2	0	1
LY 10/Carb 6/Pem 500 (Cohort 2)	0	0	4	2	1
LY 120/Carb 6/Pem 500 (Cohort 6)	0	0	0	0	0
LY 20/Carb 6/Pem 500 (Cohort 3)	0	1	2	1	1
LY 40/Carb 6/Pem 500 (Cohort 4)	0	1	2	3	0
LY 40/Carb 6/Pem 500 + R50 (Cohort 9)	0	0	2	2	1
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)	0	1	1	2	0
LY 80/Carb 6/Pem 500 (Cohort 5)	0	0	0	1	2
LY 80/Carb 6/Pem 500 + R50 (Cohort 7)	0	1	1	0	0

[back to top]

Overall Response Rate (ORR)

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01332630)
Timeframe: 8-24 weeks

Intervention	Participants (Count of Participants)
TPI 287	21

[back to top]

Visual Analogue Scale Score

The investigators are measuring the change of pain from the baseline to the 30th and 60th minutes by visual anologue scale (VAS). Visual Analogue Scale measurement is between 0 (no pain) and 100 (worst pain). A decrease of 13 or 16 mm in VAS score is accepted as a minimum clinically significant change in pain. (NCT01737840)
Timeframe: 30th and 60th minutes

Intervention	Visual Analogue Scale (Mean)
	VAS score changes at 60 minutes	VAS scores changes at 30 minutes
Pantoprazole	39.6	27.6
Ranitidine	42.3	28.3

[back to top]

Need for Additional Drug

The investigators are measuring the need for additional drug at the end of 60 minutes. (NCT01737840)
Timeframe: 60 th minute

Intervention	participants (Number)
Pantoprazole	13
Ranitidine	8

[back to top]

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment

One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units. (NCT01896557)
Timeframe: One week after randomized treatment exposure (omeprazole or ranitidine)

Intervention	P2Y12 Reactivity Units (Mean)
Omeprazole	173.54
Ranitidine	153.61

[back to top]

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.

One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as the percent change in aggregability from baseline, with the formula IPA = (on-treatment aggregability minus baseline aggregability)/baseline aggregability. Since baseline aggregation is always, per definition, equal or more than on-treatment aggregation, there is no possibility that this number might be negative. (NCT01896557)
Timeframe: One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline

Intervention	Percentage (Mean)
Omeprazole	17.4
Ranitidine	30.1

[back to top]

Comparison of the Primary Outcome With Bioimpedance Aggregometry

After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: bioimpedance aggregometry with ADP 10 mcM as reagent (NCT01896557)
Timeframe: 1 week after drug exposure

Intervention	Ohms (Mean)
Omeprazole	2
Ranitidine	2.77

[back to top]

Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)

After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: PFA-100(Collagen/ADP cartridge). (NCT01896557)
Timeframe: 1 week after drug exposure

Intervention	seconds (Mean)
Omeprazole	95.1
Ranitidine	97.2

[back to top]

Percentage of Participants With Objective Response

Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC. (NCT02999633)
Timeframe: Baseline until disease progression or death (maximum duration: 12.1 weeks)

Intervention	percentage of participants (Number)
Isatuximab	0

[back to top]

Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration

The cumulative amount of ranitidine excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Intervention	milligrams (Geometric Mean)
Ranitidine and Cured Meats Diet	91.7
Ranitidine and Noncured Meats Diet	74.1

[back to top]

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)

The cumulative amount of NDMA excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Intervention	nanograms (Median)
Ranitidine and Noncured Meats Diet	0.6
Placebo and Noncured Meats Diet	10.5
Ranitidine and Cured Meats Diet	11.9
Placebo and Cured Meats Diet	23.4

[back to top]

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)

Intervention	nanograms (Median)
Ranitidine and Cured Meats Diet	11.9
Ranitidine and Noncured Meats Diet	0.6
Placebo and Cured Meats Diet	23.4
Placebo and Noncured Meats Diet	10.5

[back to top]

Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration

The cumulative amount of DMA excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Intervention	milligrams (Geometric Mean)
Ranitidine and Noncured Meats Diet	38.8
Placebo and Noncured Meats Diet	41.1
Ranitidine and Cured Meats Diet	40.7
Placebo and Cured Meats Diet	43.1

[back to top]

AUC(0-t) of Plasma DMA

Determined for each subject using non-compartmental methods. All parameters will be reported with standard descriptive statistics including the geometric mean and coefficient of variation. Calculation of pharmacokinetic parameters will be performed using actual sampling times over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose with planned samples at 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 11, 14, and 24 h post-dose

Intervention	micrograms*hour/milliliter (Geometric Mean)
Ranitidine and Noncured Meats Diet	26.3
Placebo and Noncured Meats Diet	26.2
Ranitidine and Cured Meats Diet	20.9
Placebo and Cured Meats Diet	20.9

[back to top]

AUC(0-t) of Plasma Ranitidine

Intervention	nanograms*hour/milliliter (Geometric Mean)
Ranitidine and Cured Meats Diet	3736
Ranitidine and Noncured Meats Diet	4857

[back to top]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.03	1	0	metal allergen; nickel group element atom	epitope; micronutrient
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	7.64	13	13	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	8.37	1	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
furazolidone Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514). furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.	10.71	3	1	nitrofuran antibiotic; oxazolidines	antibacterial drug; antiinfective agent; antitrichomonal drug; EC 1.4.3.4 (monoamine oxidase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.98	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	7.44	7	6	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	14.18	47	35	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	12.04	5	3	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	13.31	36	29	aromatic ether; benzimidazoles; pyridines; sulfoxide
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	5.5	4	4	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.03	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	10.19	14	13	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.03	1	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	5.2	6	0	C-nitro compound; imidazoles	antitubercular agent
streptomycin [no description available]	1.99	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
zinc sulfate Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.	2.03	1	0	metal sulfate; zinc molecular entity	fertilizer
copper sulfate Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.	2.03	1	0	metal sulfate	emetic; fertilizer; sensitiser
nickel sulfate nickel sulfate: RN given refers to cpd with MF of Ni(2+)-H2SO4. nickel sulfate : A metal sulfate having nickel(2+) as the metal ion.	2.03	1	0	metal sulfate	allergen
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	16.04	65	47	penicillin allergen; penicillin	antibacterial drug
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	17.04	95	67	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	11.35	4	3	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	8.43	1	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.	3.37	1	1
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	5.45	2	2	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	19.06	169	100	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
bismuth Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.	19.06	169	100	metal atom; pnictogen
s 1743 Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.	5.07	3	3	magnesium salt	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
bismuth tripotassium dicitrate bismuth tripotassium dicitrate: contains tripotassium di-citratobismuthate used in gastric & duodenal ulcer therapy; do not confuse with colloidal bismuth subnitrate	7.18	11	3
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	3.37	1	1
bismuth subsalicylate bismuth subsalicylate: bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter. bismuth subsalicylate : A bismuth salt of salicylic acid.	7	5	0
peptones Peptones: Derived proteins or mixtures of cleavage products produced by the partial hydrolysis of a native protein either by an acid or by an enzyme. Peptones are readily soluble in water, and are not precipitable by heat, by alkalis, or by saturation with ammonium sulfate. (Dorland, 28th ed)	3.37	1	1
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	11.66	22	16
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	4.35	2	2
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	7	5	0	monohydroxybenzoate	plant metabolite
lactoferrin Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.	3.42	1	1

Condition	Relationship Strength	Studies	Trials
Infections, Helicobacter [description not available]	19.47	154	95
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	19.47	154	95
Infections, Coronavirus [description not available]	2.25	1	0
2019 Novel Coronavirus Disease [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1	0
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	2.25	1	0
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	2.25	1	0
Indigestion [description not available]	9.82	20	14
Dyspepsia Impaired digestion, especially after eating.	9.82	20	14
Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.	10.52	16	13
Diabetes Mellitus, Adult-Onset [description not available]	3.43	1	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	3.43	1	1
Gastroduodenal Ulcer [description not available]	9.72	21	12
Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	9.72	21	12
Curling Ulcer Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.	11.21	29	22
Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM.	11.21	29	22
Erosive Duodenitis [description not available]	3.39	1	1
Duodenitis Inflammation of the DUODENUM section of the small intestine (INTESTINE, SMALL). Erosive duodenitis may cause bleeding in the UPPER GI TRACT and PEPTIC ULCER.	3.39	1	1
Blood Pressure, High [description not available]	3.4	1	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	3.4	1	1
Colicky Pain [description not available]	2.01	1	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	2.01	1	0
Bilateral Headache [description not available]	4.34	2	2
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	4.34	2	2
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	3.37	1	1
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	3.37	1	1
Gastric Ulcer [description not available]	5.55	6	3
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	5.55	6	3
Recrudescence [description not available]	6.73	6	4
Cholera Infantum [description not available]	5.55	3	2
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	4.35	2	2
Germinoblastoma [description not available]	2.91	1	0
Cancer of Stomach [description not available]	2.91	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.91	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.91	1	0
Chronic Illness [description not available]	2	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2	1	0
Gastric Diseases [description not available]	2.91	1	0
Itching [description not available]	4.36	2	2
Taste Disorder, Anterior Tongue [description not available]	3.39	1	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	4.36	2	2
Dizzyness [description not available]	3.39	1	1
Exanthem [description not available]	3.39	1	1
Emesis [description not available]	3.39	1	1
Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.	3.39	1	1
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	3.39	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.39	1	1

ranitidine bismuth citrate

Description

Cross-References

Synonyms (20)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (165)

Study Types

Clinical Trials (51)

Trial Overview

Trial Outcomes

Number of Participants With Adverse Events

Response Rate

Bradycardia Episodes/Day

The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.

Percentage of Participants With the Occurance of Any Adverse Event.

The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy

The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

New Skin Infections

Clinical Severity Score

New Lung Infections

Number of Infections in Subjects With HIES.

Prevention of Chemical Pneumonitis

The Benefit of Advanced Notification in Promoting Informed Consent

Change in Methacholine Sensitivity

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

Percentage of Participants With Adverse Events by Category

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314

PK Parameter: Cmax of Free Carboplatin

PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

PK Parameter: AUC0-∞ of Free Carboplatin (Carb)

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)

Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])

Number of Participants With Best Overall Tumor Response

Overall Response Rate (ORR)

Visual Analogue Scale Score

Need for Additional Drug

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.

Comparison of the Primary Outcome With Bioimpedance Aggregometry

Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)

Percentage of Participants With Objective Response

Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)

Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration

AUC(0-t) of Plasma DMA

AUC(0-t) of Plasma Ranitidine

Related Drugs (35)

Related Conditions (47)